脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究

doi:10.3969/j.issn.1006-7795.2019.06.018

首都医科大学学报 ›› 2019, Vol. 40 ›› Issue (6): 911-915.doi: 10.3969/j.issn.1006-7795.2019.06.018

脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究

白向东¹, 郝雅婷¹, 张欣雪², 贺强²

1. 山西省肿瘤医院乳腺三科, 太原 030013;
2. 首都医科大学附属北京朝阳医院普外科, 北京 100020

收稿日期:2019-06-27 出版日期:2019-11-21 发布日期:2019-12-18
通讯作者: 贺强 E-mail:heqiang349@sina.com
基金资助:
国家自然科学基金面上项目（81471590）。

Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients

Bai Xiangdong¹, Hao Yating¹, Zhang Xinxue², He Qiang²

1. The Third Department of Breast Surgery, Shanxi Cancer Hospital, Taiyuan 030013, China;
2. Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

Received:2019-06-27 Online:2019-11-21 Published:2019-12-18
Supported by:
This study was supported by National Natural Science Foundation of China(81471590).

摘要/Abstract

摘要： 目的探讨脾多肽对三阴性乳腺癌术后辅助化学药物治疗（以下简称化疗）患者的临床疗效。方法将2014年1月至2017年12月间收治的80例三阴性乳腺癌患者采用数字表法随机分为对照组（n=40）和试验组（n=40），对照组采用常规的根治手术加术后辅助化疗，试验组在对照组的基础上加用脾多肽注射液，比较试验组和对照组患者的临床疗效和免疫功能。结果治疗后，试验组与对照组相比，Karnofsky功能状态评分明显增高（F=5.793，P=0.018），CD4⁺（t=5.337，P<0.001）、CD8⁺（t=9.874，P<0.001）、自然杀伤细胞（natural killer cell，NK）（t=－7.460，P<0.001）的比例及Treg细胞（t=7.113，P<0.001）都有不同程度地增高。试验组的无进展生存期（progress-free survival period，PFS）比对照组长，两组差异有统计学意义（P<0.05）。两组的上肢淋巴水肿率差异无统计学意义（P>0.05）。结论脾多肽注射液可明显提高患者免疫功能，促进生活质量改善与提高，在临床治疗领域具备进一步推广价值。

关键词: 三阴性乳腺癌, 脾多肽注射液, 无进展生存期, 免疫功能, 上肢淋巴水肿率

Abstract: Objective To explore the effect of lineal polypeptide injection combined with chemotherapy on the clinical efficacy in patients with triple-negative breast cancer. Methods Eighty patients with triple-negative breast cancer at Shanxi Provincial Cancer Hospital from January 2014 to December 2017 were enrolled in the study and randomly divided into control group with 40 cases and experimental group with 40 cases. In comparison with the control group treated with conventional postoperative chemotherapy, the experimental group was given the additional lienal polypeptide injection on the basis of the control group. The immunological function and clinical efficacy were compared. Results After treatment, the Karnofsky functional status score of the experimental group was significantly higher than that of the control group(F=5.793,P=0.018), and the proportion of CD4⁺ (t=5.337, P<0.001), CD8⁺(t=9.874,P<0.001), natural killer cell (NK) (t=-7.460,P<0.001) and Treg cells(t=7.113, P<0.001) were all increased to different degrees. The progress-free survival period (PFS) of the experimental group was longer than that of the control group, and the difference between the two groups was statistically significant (P<0.05).However, there was no statistically significant difference in the rate of upper limb lymphedema (P>0.05). Conclusion Lineal polypeptide injection can effectively improve the immune function and enhance the general life of triple-negative breast cancer patients.

Key words: triple-negative breast cancer, lienal polypeptide injection (LPI), progress-free survival period, immune function, upper limb lymphedema

中图分类号:

R737.9

白向东, 郝雅婷, 张欣雪, 贺强. 脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究[J]. 首都医科大学学报, 2019, 40(6): 911-915.

Bai Xiangdong, Hao Yating, Zhang Xinxue, He Qiang. Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients[J]. Journal of Capital Medical University, 2019, 40(6): 911-915.

参考文献

[1] Gelmon K, Dent R, Mackey J R, et al. Targeting triple-negative breast cancer:optimising therapeutic outcomes[J]. Ann Oncol, 2012, 23(9):2223-2234.
[2] Bai X, Han G, Liu Y, et al. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3[J]. Biomed Pharmacother,2018,103:1482-1489.
[3] Christenson J L, Butterfield K T, Spoepstra N S, et al. MMTV-PyMT and derived met-1 mouse mammary tumor cells as models for studying the role of the androgen receptor in triple-negative breast cancer progression[J].Horm Cancer, 2017,8(2):69-77.
[4] 王姝姝,胡保全,齐晓伟,等.新辅助化疗和辅助化疗治疗三阴性乳腺癌患者预后差异的回顾性研究[J].中华乳腺病杂志,2018,12(4):229-233.
[5] Wu Y P, Deng J, Ouyang S H, et al. Immune regulation effect of lienal polypeptides extract in Lewis lung carcinoma-bearing mice treated with cyclophosphamide[J]. Exp Biol Med (Maywood), 2018,243(1):66-77.
[6] 李文军,于代华,宗雷,等. 脾多肽注射液对脓毒症患者血清炎症因子及免疫功能的影响[J].陕西医学杂志,2019,48(4):463-466.
[7] 代平,王于理,王金辉,等.脾多肽对晚期卵巢癌化疗引起骨髓抑制影响[J].中华肿瘤防治杂志,2018,25(6):437-441.
[8] 王丹丹,陈伟贤,夏文晋,等.脾多肽联合化疗治疗乳腺癌的临床疗效观察[J].中国现代医学杂志,2017,27(3):93-96.
[9] 代平,王于理,王金辉,等.脾多肽对晚期卵巢癌化疗引起骨髓抑制影响[J].中华肿瘤防治杂志,2018,25(6):437-441.
[10] 战祥毅,隋鑫,王文萍. 乳腺癌术后上肢淋巴水肿治疗进展[J].临床军医杂志,2016,44(12):1305-1309.
[11] 王惠雪,李惠萍,杨娅娟,等.空气波压力治疗仪在预防及治疗乳腺癌术后淋巴水肿效果Meta分析[J].中华肿瘤防治杂志,2017,24(11):773-778.
[12] 宋聪睿,白玲,唐英,等.乳腺癌前哨淋巴结转移相关因素分析[J].中华肿瘤防治杂志,2016,23(18):1234-1238,1243.
[13] 鲍艳红,李薇,李青.三联疗法对乳腺癌术后上肢肿胀患者免疫功能和炎性因子的影响[J].河北医药,2018,7(40):2123-2126.
[14] 王翠娟,尚明,邵华.芳香烃受体在肿瘤发生及免疫治疗中的作用[J].中华肿瘤防治杂志,2018,25(15):1126-1130.
[15] 骆成玉.乳腺癌治疗从标准到精准微创[J].首都医科大学学报,2016,37(3):331-335.

脾多肽注射液联合术后化疗对三阴性乳腺癌患者临床疗效的研究

Clinical efficacy of lineal polypeptide injection combined with chemotherapy in triple-negative breast cancer patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	白向东, 郝雅婷, 张欣雪, 贺强. 雌激素受体阳性和阴性乳腺癌术后辅助化学药物治疗中加用脾多肽的临床免疫疗效观察[J]. 首都医科大学学报, 2019, 40(3): 443-448.
[2]	杨薇;杨华升;何秀娟;李秀惠;钱英. 槲芪散联合经动脉化疗栓塞术治疗原发性肝癌65例临床观察[J]. 首都医科大学学报, 2009, 30(1): 37-40.
[3]	毕晓郁;高丽芳;曹丽歌;陈振良;吴涛;殷召雪;苏忆兰;蒋致诚. 螺旋藻葛根片对小鼠免疫功能的影响[J]. 首都医科大学学报, 2007, 28(1): 78-80.
[4]	张永宏;吴昊;陈新月;闫惠平;温韬;檀玉芬;计云霞;武彦宁. SARS患者T细胞及其亚群数量变化的动态观察[J]. 首都医科大学学报, 2003, 24(4): 392-395.
[5]	孔祥环;褚金花;肖忠新;王虹;王淑英;李丽;李亚娟. 主营烧烤餐馆空气质量及从业人员免疫功能的调查[J]. 首都医科大学学报, 1999, 20(4): 247-249.
[6]	武宝玉;袁申元;魏民;李伯光. 实验性膜性肾小球肾炎大鼠红细胞免疫功能的初步研究[J]. 首都医科大学学报, 1999, 20(3): 178-180.
[7]	李玉兰;李郁英;安云庆;杨佩荪;刘冬梅. 谷氨酸单钠对大鼠发育和免疫功能的影响[J]. 首都医科大学学报, 1997, 18(3): 218-221.